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Abstract
Whole brain radiotherapy (WBRT) is associated with memory dysfunction. As part of NRG 
Oncology RTOG 0933, a phase II study of WBRT for brain metastases that conformally avoided 
the hippocampal stem cell compartment (HA-WBRT), memory was assessed pre- and post-HA-
WBRT using both traditional and computerized memory tests. We examined whether the 
computerized tests yielded similar findings and might serve as possible alternatives for assessment 
of memory in multi-institution clinical trials. Adult patients with brain metastases received HA-
WBRT to 30 Gy in ten fractions and completed Hopkins Verbal Learning Test-Revised (HVLT-R), 
CogState International Shopping List Test (ISLT) and One Card Learning Test (OCLT), at 
baseline, 2 and 4 months. Tests’ completion rates were 52–53 % at 2 months and 34–42 % at 4 
months. All baseline correlations between HVLT-R and CogState tests were significant (p ≤ 
0.003). At baseline, both CogState tests and one component of HVLT-R differentiated those who 
were alive at 6 months and those who had died (p ≤ 0.01). At 4 months, mean relative decline was 
7.0 % for HVLT-R Delayed Recall and 18.0 % for ISLT Delayed Recall. OCLT showed an 8.0 % 
increase. A reliable change index found no significant changes from baseline to 2 and 4 months for 
ISLT Delayed Recall (z = −0.40, p = 0.34; z = −0.68, p = 0.25) or OCLT (z = 0.15, p = 0.56; z = 
0.41, p = 0.66). Study findings support the possibility that hippocampal avoidance may be 
associated with preservation of memory test performance, and that these computerized tests also 
may be useful and valid memory assessments in multi-institution adult brain tumor trials.
Keywords
NRG Oncology RTOG 0933; Neurocognitive; HVLT-R; ISLT; OCLT
Introduction
Formal measurement of neurocognitive functioning (NCF) is included in a subset of brain 
cancer trials to quantify impact of tumors and treatments on cognition, particularly memory. 
While there is no shortage of NCF tests, a handful are familiar to many investigators, as they 
originated as early as the 1940s and have appeared often in important recent trials. One 
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distinct advantage of consistent use of a small number of tests is that doing so promotes 
efforts to standardize NCF activity across studies [1].
At the same time, strict adherence to a particular protocol may paradoxically discourage 
inclusion of NCF in trials. NCF endpoints are often viewed as burdensome for both patients 
and staff [2], yet NCF can be defined and measured in many ways, and while one study may 
require detailed examination of cognition to address questions of interest properly, another 
might require only selective examination or even use of a single proxy. Another unintended 
consequence of limiting trials to a particular subset of tests is that it may deter innovation 
within the choice of tests used for measurement. For example, the suitability of some NCF 
tests for repeated administration for purposes of detecting change over time may be 
questioned [3].
When NCF is included in a trial, often it serves as the primary endpoint, and memory, 
generally the auditory/verbal domain, is frequently the focus, as it is a major component of 
quality of life [4] and susceptible to early and sometimes severe deterioration due to tumors 
[5] and their treatments [6]. Paper and pencil tests are most often chosen for memory 
assessment in adult cancer patients; although, computerized tests are used often in some 
brain conditions where cognition is compromised, such as concussion [7] and Alzheimer’s 
disease [8]. Recently, computerized tests have begun to be incorporated into cancer studies 
[9, 10], including pediatric populations [11].
As part of NRG Oncology RTOG 0933 [12], a phase II study of patients with brain 
metastases who underwent whole brain radiotherapy (WBRT) but with conformal avoidance 
of the peri-hippocampal stem cell region (HA-WBRT), two computerized tests of memory 
were included as secondary endpoints, along with the Hopkins Verbal Learning Test-Revised 
(HVLT-R) [13], a traditional test of memory used often in adult cancer trials that measured 
the study’s primary endpoint. Of interest was whether the computerized tests yield findings 
similar to HVLT-R and whether they might serve as possible alternatives for assessment of 
memory, within the context of a multi-institution cooperative group trial.
Materials and methods
Protocol approval was received from the Institutional Review Board at each study site and 
informed consent obtained from each patient prior to participation. All sites met technology 
and training requirements to ensure ability to perform HA-WBRT and administer NCF tests 
properly.
Patients and intervention
As detailed in our primary publication [12], 113 patients were accrued (average monthly 
accrual was 5.9) from March 31, 2011, to November 1, 2012, with 13 patients excluded due 
to lack of protocol treatment or study criteria ineligibility, resulting in 100 analyzable 
patients (median age 61, 52 % female). All patients had brain metastases outside a 5 mm 
margin around the hippocampus. Patient selection and treatment parameters matched the 
criteria used in PCI-P-120-9801 [14], a phase III trial of patients who received WBRT (i.e., 
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no conformal avoidance of the peri-hippocampal stem cell region) for brain metastases and 
who served as the pre-specified historical control for this study.
WBRT is associated with memory dysfunction in some patients [15, 16], as well as patient-
reported quality of life [17]. The historical control identified a mean relative decline of 30 % 
from baseline to 4-month follow-up in HVLT-R Delayed Recall. The present study 
employed intensity-modulated radiotherapy (IMRT) techniques [18] to allow coverage of the 
planning target volume while conformally avoiding the hippocampal neural stem cell niche, 
an area implicated in new memory formation [19]. Treatment consisted of HA-WBRT to 30 
Gy in 10 fractions.
NCF assessment
Memory assessment was conducted at baseline, 2 and 4 months. The 12-month data were 
not analyzed due to low completion (8–10 %, with more than 50 % loss due to death). 
Because HVLT-R Delayed Recall served as the measure for the primary endpoint, with 
statistical comparison to HVLT-R Delayed Recall findings from the historical control, the 
usual sequence of HVLT-R components was altered to conform to that study’s method, 
which consisted of 3 learning trials, followed immediately by the recognition component, a 
delay period of 20 min, and then delayed recall; this altered format has also been used in 
other phase III cooperative group research [20, 21].
Two computerized tests of memory were also included. The International Shopping List Test 
(ISLT) [22, 23] is a computer-administered and scored, 16-item (there are shorter versions) 
auditory/verbal list-learning task with psychometric properties including reliability and 
validity comparable to traditional list-learning tasks [24], but possibly with less 
susceptibility to proactive interference, a potential confound [25]. As with HVLT-R and 
other word-list tests, words (unseen by the patient) are read aloud by an examiner and 
patients immediately recall, in any order, as many words as possible from the list. For ISLT, 
timing of oral presentation of the words is cued by their appearance onscreen, and the 
examiner enters responses by clicking the list’s words on the computer’s screen (non-list 
words said aloud by the patient are indicated by clicking an “Other Word” button). There are 
3 learning trials and one delayed recall trial that follows 20 min later. Because each list is 
pseudo-randomly generated from a pool of 128 words, 8 lists are possible without overlap. 
Content is drawn from food items common to specific geographic locations and languages. 
Instructions are available in multiple languages (including variants). A sample screen view 
of the test is shown in Fig. 1a.
The One Card Learning Test (OCLT), which demonstrates good psychometric properties 
including reliability and validity [26–29], involves a visuoperceptual pattern separation 
paradigm [30] within a continuous visual recognition task [31], where standard playing 
cards are presented one at a time in the center of the computer’s screen. Pattern separation 
appears to be a key function of memory activity within the hippocampus and particularly the 
dentate gyrus as demonstrated by fMRI [32, 33]. As each card is presented, the patient must 
indicate whether that card has been presented previously in the task by pressing buttons 
representing “yes” or “no.” The software can generate essentially unlimited content 
sequences. Instructions are available in multiple languages (including variants) and OCLT 
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requires no verbal response or delay period between portions of the test. This version of 
OCLT used 88 items. An illustration of the test is shown in Fig. 1b.
The sequence of administration in this protocol was HVLT-R, ISLT and OCLT (OCLT was 
administered during the 20-min period between ISLT Immediate and Delayed Recall) at 
baseline and 4 months, to allow for proper comparison to historical control. At 2-months 
follow-up, as a check for potential effects resulting from the administration sequence of the 
tests, their administration sequence was altered to ISLT, OCLT and HVLT-R. (Sequence of 
administration was not analyzed due to limited completion rates at 2 and 4 months.) At each 
testing session, there was a break of about 10 min with intervening activity between the two 
list-learning tasks to lessen the possibility of interference effects.
Statistical analyses
Raw test scores were used for statistical analyses. Patients served as their own controls. 
Mean relative decline from baseline for each test was assessed with the following formula: 
baseline—follow-up/baseline. ISLT and OCLT were further examined via a Reliable Change 
Index (RCI). RCIs may be calculated in a number of ways, but they all are a means of 
controlling the sources of error associated with repeated NCF assessments. The method 
chosen for this study, which uses the within-subject standard deviation, or mean square error 
from a linear regression model as the standard error of measurement, is described in detail 
elsewhere [34]. Associations between the 3 tests were evaluated using Spearman correlation 
coefficients. Due to the rates of patient deaths throughout the study, cases also were split into 
two groups to allow for comparisons between those who were alive at 6 months and those 
who had died by 6 months; these were evaluated with the Wilcoxon rank-sum test. Because 
the study involved multiple comparisons, which increases the likelihood of Type 1 error, 
significance level was set at 0.01, rather than 0.05, for all analyses.
Results
Completion
Of the 100 eligible patients, 92 and 89, respectively, completed HVLT-R, and ISLT and 
OCLT, prior to HA-WBRT. Completion for HVLT-R at 2 months was 53 (53 %) cases 
analyzed, with 23 not analyzed and 24 deaths; whereas, at 4 months the numbers were 42 
(42 %), 17 and 41, respectively. For the CogState tests, at 2 months there were 52 (52 %) 
cases analyzed, with 24 not analyzed and 24 deaths, and at 4 months there were 34 (34 %), 
25 and 41. For most tests, the largest number of non-analyzable cases was due to data not 
submitted.
Relative decline and RCI
At 4 months, the mean relative decline was 7.0 % (95 % confidence interval [CI] −4.7–
18.7 %) for HVLT-R Delayed Recall and 18.0 % (95 % CI 5.5–30.5 %) for ISLT Delayed 
Recall. OCLT showed an 8.0 % increase (95 % CI −16.9–0.90 %). A reliable change index 
(mean = 0, SD = 1) found no significant change from baseline to 2 months and from 
baseline to 4 months for ISLT Delayed Recall (z = −0.40, p = 0.34; z = −0.68, p = 0.25, 
respectively) or OCLT (z = 0.15, p = 0.56; z = 0.41, p = 0.66, respectively).
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Association among the tests
Spearman correlation coefficients are shown in Table 1. All baseline correlations among the 
3 tests were significant (0.31–0.71; p ≤ 0.003). For the follow-up time points, associations 
between HVLT-R and ISLT Immediate Recall and Delayed Recall (both involve recall of 
newly presented material, as when taking an essay test in school) and HVLT-R Immediate 
Recognition and OCLT (both involve recognition of material where newly presented 
information must be differentiated from that which was not presented, as when taking a 
yes/no choice test in school) were emphasized.
At 2 and 4 months, Immediate Recall correlations between HVLT-R and ISLT were 
significant (0.73 and 0.80, p ≤ 0.0001), as were correlations between HVLT-R and ISLT 
Delayed Recall (0.72 and 0.66, p ≤ 0.0001). A relatively strong association may be expected 
between these 2 tests since both involve hearing a list of words and recalling them aloud. 
Correlations between HVLT-R Immediate Recognition and OCLT were .45 (2 months, p = 
0.001) and .46 (4 months, p = 0.007); a relatively weaker association may be expected 
between HVLT-R and OCLT, as the two tests represent different NCF domains (auditory 
versus visuoperceptual), impart different stimuli (words versus playing cards) and involve 
different formats (yes/no recognition of words versus continuous visual recognition of 
standard playing cards).
Alive versus deceased at 6 months
Median survival was 6.8 months (95 % CI 4.8–10.9 months). As shown in Table 2, baseline 
Wilcoxon rank-sum tests found that 4 of the 6 memory test components differed for those 
who were alive at 6 months and those who had died by 6 months. Those alive at 6 months 
scored higher at baseline for HVLT-R Immediate Recall (median score of 25 for patients 
alive at 6 months versus 20 for patients deceased at 6 months, p = 0.008), ISLT Immediate 
Recall (27 vs. 23, p = 0.001) and Delayed Recall (10 vs. 7, p = 0.001), and OCLT (0.95 vs. 
0.88, p = 0.001), suggesting that the sample may have varied in degree of illness at baseline. 
There was a trend toward significance for HVLT-R Delayed Recall (10 vs. 7, p = 0.022), but 
the relationship was not significant for HVLT-R Immediate Recognition (12 vs. 11, p = 
0.10). Figure 2a displays HVLT-R and ISLT Immediate Recall scores at baseline, 2 and 4 
months; the two groups appeared to diverge over time. Figure 2b displays HVLT-R and ISLT 
Delayed Recall scores across these time intervals; the two groups appeared to continue to 
differ over time. Figure 3a, b display HVLT-R Immediate Recognition and OCLT scores 
across the intervals, respectively.
Discussion
The present study supports the primary findings of NRG Oncology RTOG 0933 [12], which 
found that HA-WBRT is associated with preservation of performance on a memory test used 
often in adult cancer trials. It also provides preliminary evidence that two other memory 
tests, CogState computerized International Shopping List Test and One Card learning Test, 
may be useful and valid measures of memory in multi-institution adult brain tumor trials. 
Results are consistent with evidence from a validation study [35] that found 4 CogState 
computerized tests (including OCLT) administered to adult brain tumor patients (primarily 
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glioblastoma) compared favorably with a traditional paper and pencil battery that included 
HVLT-R, suggesting that those tests may be reliable and valid measures with adult brain 
tumor populations. Further study of HA-WBRT is needed to determine whether aspects of 
cognition, including memory but also other domains such as executive functions, may 
benefit from the techniques.
The original HVLT [36] included only Immediate Recall and Immediate Recognition tasks 
to avoid a need for a delay period (e.g., 20 min) and minimize total task time. Nevertheless, 
delayed recall is a useful means of measuring memory (whereas immediate recall is often 
used to assess learning) and a delayed recall component was sometimes added by 
researchers, as it was when the test was formally revised and became HVLT-R [13]. In that 
revision, the recognition component was moved so that it followed delayed recall, which is 
the format used in most memory list tasks. To remain consistent with the format of the pre-
specified historical control study, this study kept the recognition component between 
conclusion of Immediate Recall and beginning of Delayed Recall, which limits 
generalizability of these data to studies where HVLT-R Recognition followed Delayed 
Recall.
Compliance with NCF measurement points can be difficult for patients with brain tumors 
and may be less than 50 % in multi-institution studies [37]. In this study, completion rates at 
4 months for all tests were below 50 %, an important limitation that complicates our 
understanding of the effects of treatment on memory. Compliance may have been especially 
challenging because patients were asked to undergo three memory tests at each session. The 
computerized tests showed a greater drop in compliance at 4 months than did HVLT-R, 
possibly due to their following HVLT-R in administration sequence; patients were asked to 
complete all tests at each testing session, but were urged, at minimum, to complete the 
HVLT-R since it served as the primary endpoint.
Previous research has shown that NCF decline correlates with tumor growth [38], and this 
study, as with others [39, 40], found that better memory at baseline was associated with 
longer survival. It is unclear why HVLT-R Immediate Recognition and Delayed Recall, 
unlike HVLT-R Immediate Recall, failed to maintain a performance differentiation between 
those who had died at 6 months and those who remained alive, when the difference was 
identified by both ISLT conditions and OCLT. One possibility is that it reflects an artifact of 
the study’s ordering of HVLT-R components. However, it is also possible that certain 
features of the computerized tests may have offered additional precision. For example, 
unlike HVLT-R, ISLT does not group words according to semantic categories, whereby 
content may be organized strategically by the patient to improve performance [41, 42]. 
Further, use of semantic clustering may increase between a first and a second session [43]. 
Unlike ISLT, HVLT-R content may be particularly susceptible since it includes emotionally-
laden categories such as weapons (e.g., “bomb”) and alcoholic beverages (e.g., “bourbon”), 
and there is evidence that emotionally-arousing content is more readily semantically 
categorized [44]. OCLT uses neutral, universal content and does not present an opportunity 
to use strategy to improve performance. Further, it minimizes score range restrictions (word 
lists usually contain 12–16 words) by computing the arcsine transformation of the square 
root of the proportion of correct responses across a large number of items. Last, memory 
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assessment in cancer trials has historically relied on auditory list-learning tasks and OCLT 
offers investigators the ability to assess visuoperceptual memory.
Potential advantages of computerized NCF tests
As with this study, since NCF measurement often suffers from data completion failure at 
follow-up time points, tests should obtain as much information as possible at each 
assessment session. Without adding to burden, software-based tests may automatically 
capture multiple scores, including accuracy, various error subtypes and speed (in 
milliseconds rather than whole seconds timed by hand), with some serving as potential 
covariates.
Computerized formats allow a research assistant (psychometricians are not required) to 
focus solely on proper test administration and may reduce sources of potential error by 
automating data capture and scoring. They also may include useful features such as direct 
data upload to real-time databases, nearly unlimited numbers of differing test forms and 
elimination of time delay periods (e.g., continuous recognition formats) between portions of 
a test such as required for immediate and delayed recall. Further, because statistical 
measures for differentiating change from stability need not require access to normative data 
sets, NCF tasks can be pre-configured to sample populations’ capabilities by a priori 
selection of task length, format or difficulty level. For example, Children’s Oncology Group 
[45] is studying use of computerized tests in pediatric populations where level of difficulty 
can be scaled from children to adults, offering potential for lifespan harmonization of NCF 
data. Perhaps surprising is evidence that even the elderly can enjoy computer-based testing 
and that some prefer it to paper and pencil tests [46].
Use of technology may promote internationalization of studies and allow for greater choice 
as to where data are collected, including remote login for test administration (e.g., a primary 
care clinic or even the patient’s home). By removing barriers to innovative trials design, 
protocols might include more frequent NCF sessions and detailed charting of performance 
curves. Studies have found online administration in patients’ homes to be practical with 
post-surgical cardiac [47], multiple sclerosis [48] and concussion patients [49]. Cancer 
patients appear to find interacting with technology to be the same or preferable to paper and 
pencil formats [35, 50].
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Fig. 1. 
a Sample screen from ISLT. b Illustration of presentation of OCLT stimuli
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Fig. 2. 
a ISLT and HVLT-R Immediate Recall raw scores. b ISLT and HVLT-R Delayed Recall raw 
scores
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Fig. 3. 
a HVLT-R Immediate Recognition raw scores. b OCLT raw scores
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Table 1
Spearman correlation coefficients, 95 % confidence intervals, and significance values
CogState HVLT-R
Immediate Recall Immediate Recognition Delayed Recall
Baseline correlations
ISLT Immediate Recall (n = 89) (n = 89) (n = 89)
0.71 0.62 0.38
(0.59, 0.80) (0.47, 0.73) (0.19, 0.55)
<.0001 < .0001 0.0002
ISLT Delayed Recall (n = 88) (n = 88) (n = 88)
0.67 0.67 0.42
(0.53, 0.77) (0.53, 0.77) (0.23, 0.58)
<.0001 < .0001 < .0001
OCLT (n = 89) (n = 89) (n = 89)
0.44 0.38 0.31
(0.25, 0.59) (0.18, 0.54) (0.11, 0.49)
<.0001 0.0003 0.0030
2-month correlations
ISLT Immediate Recall (n = 48) (n = 49) (n = 49)
0.73 0.62 0.76
(0.56, 0.84) (0.41, 0.77) (0.61, 0.86)
<.0001 < .0001 < .0001
ISLT Delayed Recall (n = 48) (n = 49) (n = 49)
0.73 0.58 0.72
(0.56, 0.84) (0.36, 0.74) (0.54, 0.83)
<.0001 < .0001 < .0001
OCLT (n = 47) (n = 48) (n = 48)
0.22 0.45 0.25
(−0.07, 0.48) (0.19, 0.65) (−0.04, 0.50)
0.1328 0.0012 0.0909
4-month correlations
ISLT Immediate Recall (n = 32) (n = 32) (n = 32)
0.80 0.46 0.73
(0.63, 0.90) (0.13, 0.69) (0.51, 0.86)
<.0001 0.0087 < .0001
ISLT Delayed Recall (n = 33) (n = 33) (n = 33)
0.59 0.41 0.66
(0.31, 0.78) (0.07, 0.66) (0.40, 0.82)
0.0003 0.0187 < .0001
OCLT (n = 33) (n = 33) (n = 33)
0.14 0.46 0.19
(−0.21, 0.46) (0.14, 0.69) (−0.16, 0.50)
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CogState HVLT-R
Immediate Recall Immediate Recognition Delayed Recall
0.4273 0.0068 0.2804
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Table 2
Baseline raw score* distributions and significance values by status at 6 months
Alive at 6 months (n = 49) Died by 6 months (n = 43) P value§
ISLT Immediate Recall (n = 47) (n = 42)
 Median 27 23 0.0012
 Min–Max 8–40 0–35
ISLT Delayed Recall (n = 47) (n = 42)
 Median 10 7 0.0005
 Min–Max 0–16 0–13
OCLT (n = 47) (n = 42)
 Median 0.9473 0.8826 0.0014
 Min–Max 0.47–1.23 0.41–1.09
HVLT Immediate Recall (n = 49) (n = 43)
 Median 25 20 0.0078
 Min–Max 10–34 8–35
HVLT-Delayed Recall (n = 49) (n = 43)
 Median 10 7 0.0223
 Min–Max 2–12 0–12
HVLT-Immediate Recognition (n = 49) (n = 43)
 Median 12 11 0.0945
 Min–Max 0–12 4–12
§P value from Wilcoxon rank-sum test
*
Higher scores reflect better performance for all tests. Scores for HVLT-R and ISLT are in whole words, with score ranges = 0–36 for HVLT-R 
Immediate Recall, 0–12 for HVLT-R Immediate Recognition and HVLT-R Delayed Recall, and 0–48 for ISLT Immediate Recall and 0–16 for ISLT 
Delayed Recall. Scores for OCLT are arcsine transformations of the square root of the proportion of correct responses and range from 0 to 1.57
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